Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next generation statins and anti-fungals, is proud to announce it has received a Gold Sustainability rating from EcoVadis.
Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next generation statins and anti-fungals, is proud to announce it has received a Gold Sustainability rating from EcoVadis. This affirms Centrient Pharmaceuticals’ commitment to environmental and social sustainability and underlines its position as a sustainable leader in the generics pharmaceutical industry.
The Gold Sustainability rating ranks Centrient Pharmaceuticals in the top 4% of the companies assessed by EcoVadis in the manufacture of basic pharmaceutical products and pharmaceutical preparations industry.
“We are very proud that EcoVadis has awarded Centrient with a Gold rating”, says Karl Rotthier, CEO at Centrient Pharmaceuticals. “Our efforts as a sustainability leader in our generics industry are being recognised by a renowned independent third party. This further demonstrates why our customers and partners can trust our sustainability credentials.”
“We are at the forefront of sustainable production of antibiotics with the use of our proprietary, environmentally friendly technologies. We have now reached our target of the highest Ecovadis rating possible. However, our commitment does not stop here. As a leader in our industry we are continuously striving for further improvements in each of the areas of Environment, Sustainable Procurement, Fair Labour and Human Rights, and Ethics,” Mr Rotthier continues.
Centrient Pharmaceuticals’ products help millions of people to fight life-threatening illness and live healthier lives. Sustainability is at the heart of everything the company does, with priorities set on reducing environmental impact, improving human health and social impact, and combating further spread of AMR (antimicrobial resistance).
EcoVadis is the world’s most trusted provider of business sustainability ratings, providing detailed assessments of business’ environmental, social and ethical performance. Annually, EcoVadis assesses around 55,000 suppliers from 155 countries and 198 purchasing categories.
The EcoVadis criteria are built on international CSR standards including the United Nations Global Compact, the Global Reporting Initiative (GRI), ISO 26000 and the UN Guiding Principles for Business and Human Rights.
------------------------------
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.
We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2000 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.
Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.
For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-mail: alice.beijersbergen@centrient.
Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial
performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.
